Amgen (NASDAQ:AMGN) is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of “America’s Greatest Workplaces” by Newsweek, one of “America’s Climate Leaders” by USA Today and one of the “World’s Best Companies” by TIME.
RBC Capital Raises Price Target on Amgen (NASDAQ:AMGN) to $253 From $250, Maintains Sector Perform Rating.
RBC Capital Raises Price Target on Amgen (NASDAQ:AMGN) to $253 From $250 Read Post »
Amgen (NASDAQ:AMGN) reported Q2 non-GAAP diluted earnings of $5.00, up from $4.65 a year earlier. Analysts surveyed by Capital IQ expected $4.49. Revenue for the quarter ended June 30 was $6.99 billion, up from $6.59 billion a year earlier. Analysts surveyed by Capital IQ expected $6.68 billion. The company said it now expects fiscal 2023 non-GAAP diluted earnings of $17.80 to $18.80 per share, up from its prior guidance of $17.60 to $18.70. Analysts surveyed by Capital IQ are expecting $17.70. Revenue for the year is now projected to be in the range of $26.60 billion to $27.40 billion, the company said. That compares with its prior guidance of $26.20 billion to $27.30 billion. Analysts surveyed by Capital IQ are looking for $27.32 billion. The company also said it expects share buybacks not to exceed $500 million.
Amgen (NASDAQ:AMGN) Q2 Non-GAAP Earnings, Revenue Increase; 2023 Guidance Boosted Read Post »
Amgen (NASDAQ:AMGN) Q2 EPS $5.00 Vs. $4.65 a Year Ago, Beats the FactSet Consensus $4.49。
Amgen (NASDAQ:AMGN) Q2 EPS $5.00, Beats the FactSet Consensus $4.49 Read Post »
Amgen (NASDAQ:AMGN) Guides For 2023 EPS of $17.80-$18.80 on Revenue of $26.6-$27.4 Billion, Vs CIQ Analyst Consensus of $17.70/Share on Revenue of $27.3 Billion。
Amgen (NASDAQ:AMGN) Guides For 2023 EPS of $17.80-$18.80 Read Post »
UBS Adjusts Amgen (NASDAQ:AMGN) Price Target to $250 From $248, Maintains Neutral Rating.
UBS Adjusts Amgen (NASDAQ:AMGN) Price Target to $250 From $248 Read Post »
Oppenheimer analyst Jay Olson maintains Amgen (NASDAQ:AMGN) with a Outperform and lowers the price target from $292 to $290.
Oppenheimer lowered Amgen (NASDAQ:AMGN) price target from $292 to $290 Read Post »
Amgen (NASDAQ:AMGN) said it expects full-year 2023 non-GAAP diluted earnings of $17.60 to $18.70, up from the previous guidance of $17.40 to $18.60. Analysts surveyed by Capital IQ expect $17.86. The company expects revenue for the year of $26.2 billion to $27.3 billion, up from the previous guidance of $26.0 billion to $27.2 billion. Analysts surveyed by Capital IQ expect $28.72 billion.
Amgen (NASDAQ:AMGN) Raised 2023 Guidance Read Post »
The biotechnology company guided for revenue between $26.2 billion and $27.3 billion, earnings per share of $15.38 to $16.59 and adjusted earnings between $17.60 and $18.70 a share. Amgen previously forecast revenue of $26 billion to $27.2 billion, earnings per share between $13.16 and $14.41, and adjusted earnings of $17.40 to $18.60 a share. The company said its outlook excludes any contribution from its acquisition of Horizon Therapeutics PLC, which is expected to close in the first half of 2023. Chief Executive Robert Bradway said demand for its products globally resulted in 14% volume growth in the first quarter.
Amgen(NASDAQ:AMGN) Raises 2023 Revenue, EPS Outlook Read Post »
US drugmaker Amgen (NASDAQ:AMGN) said it would lay off about 450 further jobs, less than 2 percent of its workforce, citing drug price pressures, as well as the impact of high inflation. At the end of January, the company announced 300 layoffs.
Amgen (NASDAQ:AMGN) announced 450 job cuts for the second time this year Read Post »
On February 6, Amgen Inc. (NASDAQ:AMGN) announced its fourth quarter and full year 2022 financial results. For the fourth quarter of 2022, the Company generated total revenue of $6.8 billion and GAAP earnings per share of $3.00, and for the full year 2022, total revenue of $26.3 billion and GAAP earnings per share of $12.11. Amgen said it expects to complete the acquisition of Horizon Therapeutics in the first half of this year.